Global Markets Direct’s, 'Uterine Fibroids - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Uterine Fibroids, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Fibroids. Uterine Fibroids - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Uterine Fibroids. - A review of the Uterine Fibroids products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Uterine Fibroids pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Uterine Fibroids. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Uterine Fibroids pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Uterine Fibroids - Pipeline Review, H1 2013 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Uterine Fibroids Overview 7 Therapeutics Development 8 An Overview of Pipeline Products for Uterine Fibroids 8 Uterine Fibroids Therapeutics under Development by Companies 10 Uterine Fibroids Therapeutics under Investigation by Universities/Institutes 12 Late Stage Products 13 Comparative Analysis 13 Mid Clinical Stage Products 14 Comparative Analysis 14 Early Clinical Stage Products 15 Comparative Analysis 15 Discovery and Pre-Clinical Stage Products 16 Comparative Analysis 16 Uterine Fibroids Therapeutics - Products under Development by Companies 17 Uterine Fibroids Therapeutics - Products under Investigation by Universities/Institutes 18 Companies Involved in Uterine Fibroids Therapeutics Development 19 Takeda Pharmaceutical Company Limited 19 Neurocrine Biosciences, Inc. 20 Kissei Pharmaceutical Co., Ltd. 21 Bayer AG 22 Repros Therapeutics Inc. 23 HRA Pharma, SA 24 Tokai Pharmaceuticals, Inc. 25 Uterine Fibroids - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 TAK-385 - Drug Profile 31 Product Description 31 Mechanism of Action 31 RandD Progress 31 telapristone acetate - Drug Profile 32 Product Description 32 Mechanism of Action 32 RandD Progress 32 ulipristal acetate - Drug Profile 34 Product Description 34 Mechanism of Action 34 RandD Progress 34 ulipristal acetate - Drug Profile 36 Product Description 36 Mechanism of Action 36 RandD Progress 36 mifepristone - Drug Profile 38 Product Description 38 Mechanism of Action 38 RandD Progress 38 KLH-2109 - Drug Profile 39 Product Description 39 Mechanism of Action 39 RandD Progress 39 BAY-1002670 - Drug Profile 40 Product Description 40 Mechanism of Action 40 RandD Progress 40 GnRH Antagonists - Drug Profile 41 Product Description 41 Mechanism of Action 41 RandD Progress 41 Non-Steroidal Progesterone Agonist - Drug Profile 42 Product Description 42 Mechanism of Action 42 RandD Progress 42 Uterine Fibroids Therapeutics - Drug Profile Updates 43 Uterine Fibroids Therapeutics - Discontinued Products 53 Uterine Fibroids Therapeutics - Dormant Products 54 Uterine Fibroids - Product Development Milestones 55 Featured News and Press Releases 55 Jul 30, 2012: FDA Schedules Meeting With Repros To Discuss Phase II Protocol For Proellex For Treatment Of Endometriosis 55 Jul 23, 2012: Repros's Proellex-V Shows Consistent Efficacy In Phase II Study Of Uterine Fibroids 55 Apr 30, 2012: Repros's Proellex-V Clears Hurdle In Uterine Fibroid Program 56 Mar 12, 2012: Watson Initiates US Phase III Clinical Trial Of Esmya 57 Feb 27, 2012: HRA Pharma's Esmya Receives European Commission Marketing Authorization For Pre-Operative Treatment Of Uterine Fibroids 58 Feb 02, 2012: PregLem Announces Full Results Of PEARL I And II Studies Of Esmya Published In New England Journal Of Medicine 59 Jan 04, 2012: FDA Accepts Repros's Investigational New Drug Application For Proellex-V For Treatment Of Uterine Fibroids 61 Jan 03, 2012: Repros Completes Dosing In Phase II Low-Dose Oral Proellex Trial 62 Dec 16, 2011: PregLem Receives Positive EMA/CHMP Opinion For Esmya For Pre-Operative Treatment Of Uterine Fibroids 63 Dec 15, 2011: CHMP Recommends Granting Of Marketing Authorization For Esmya 64 Appendix 66 Methodology 66 Coverage 66 Secondary Research 66 Primary Research 66 Expert Panel Validation 66 Contact Us 67 Disclaimer 67
List of Tables
Number of Products Under Development for Uterine Fibroids, H1 2013 8 Products under Development for Uterine Fibroids - Comparative Analysis, H1 2013 9 Number of Products under Development by Companies, H1 2013 11 Number of Products under Investigation by Universities/Institutes, H1 2013 12 Comparative Analysis by Late Stage Development, H1 2013 13 Comparative Analysis by Mid Clinical Stage Development, H1 2013 14 Comparative Analysis by Early Clinical Stage Development, H1 2013 15 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 16 Products under Development by Companies, H1 2013 17 Products under Investigation by Universities/Institutes, H1 2013 18 Takeda Pharmaceutical Company Limited, H1 2013 19 Neurocrine Biosciences, Inc., H1 2013 20 Kissei Pharmaceutical Co., Ltd., H1 2013 21 Bayer AG, H1 2013 22 Repros Therapeutics Inc., H1 2013 23 HRA Pharma, SA, H1 2013 24 Tokai Pharmaceuticals, Inc., H1 2013 25 Assessment by Monotherapy Products, H1 2013 26 Assessment by Stage and Route of Administration, H1 2013 28 Assessment by Stage and Molecule Type, H1 2013 30 Uterine Fibroids Therapeutics - Drug Profile Updates 43 Uterine Fibroids Therapeutics - Discontinued Products 53 Uterine Fibroids Therapeutics - Dormant Products 54
List of Figures
Number of Products under Development for Uterine Fibroids, H1 2013 8 Products under Development for Uterine Fibroids - Comparative Analysis, H1 2013 9 Products under Development by Companies, H1 2013 10 Products under Investigation by Universities/Institutes, H1 2013 12 Late Stage Products, H1 2013 13 Mid Clinical Stage Products, H1 2013 14 Early Clinical Stage Products, H1 2013 15 Discovery and Pre-Clinical Stage Products, H1 2013 16 Assessment by Monotherapy Products, H1 2013 26 Assessment by Route of Administration, H1 2013 27 Assessment by Stage and Route of Administration, H1 2013 28 Assessment by Molecule Type, H1 2013 29 Assessment by Stage and Molecule Type, H1 2013 30